Full-Time

Vice President

Translational Science

Confirmed live in the last 24 hours

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Develops treatments for eye care diseases

Biotechnology
Healthcare

Compensation Overview

$259.5k - $363.3kAnnually

+ Bonus + Stock Equity

Expert

Irvine, CA, USA

Hybrid work environment; remote work is an option.

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis

You match the following Tarsus Pharamceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • PhD or MD/PhD degree in Biology, Pharmacology, Molecular or Cell biology or related life sciences field with 15+ years’ experience and a minimum of 10+ years in the pharmaceutical or industry setting.
  • In-depth understanding and recognized scientific leader with expertise in scientific drug development for assets progressing through pre-clinical and IND-enabling studies and/or Phase I/II trials.
  • Superior knowledge and solid understanding of emerging research, mechanisms of action and disease models in anterior and posterior segment eye care diseases, preclinically and clinically.
  • Knowledge of the clinical landscape in ophthalmology indications with good understanding of novel agents and impact to this landscape.
  • Excellent oral and written communication skills, including writing, reviewing, and editing scientific documents.
  • Superior interpersonal skills, diplomacy, and positive-influencing abilities.
  • Exceptional communication, influencing and partnering skills to drive decision-making within a multi-disciplinary, matrix teams.
  • Ability to demonstrate effective leadership behaviors to ensure effective outcomes, including business agility as well as a curious, open-minded, and solution focused mindset.
  • Effective project management skills.
  • Strong presentation skills; must be able to provide succinct, strategic, and actionable insights to senior executives.
  • Proactive self-starter who can lead work independently, with the ability to see the next step and anticipate issues.
  • Scientifically independent.
  • Enterprise and entrepreneurial mindset.
Responsibilities
  • Subject Matter Expert in Pharmacology, Pathophysiology and drug target biology for both anterior and posterior segment diseases.
  • Establish and maintain strong external partnerships with key opinion leaders, academic institutions and other external partners and be seen as a scientific thought leader in the field of ophthalmology.
  • Partner with key internal experts across the company including Clinical Development, Innovation Lab and Business Development (BD) to drive translational strategy from preclinical development through candidate selection and contribute to translational strategies in early clinical development through early Proof of Concept.
  • Establish stage-appropriate project translational strategy for a differentiated asset to address unmet patient need with key 'Go/No Go' decision points.
  • Design and execute non-clinical experiments to support MOA-related translational questions as well as overall understanding of the disease treatment approaches.
  • Build and develop deep internal expertise in disease areas within ophthalmology, which are prioritized by the company. Identify possible mechanisms, disease models, preclinical POC approaches.
  • Generate clear, testable translational hypothesis to address unmet needs (mechanism of action, pharmacodynamics, patient selection).
  • Identify most relevant models, liaise with the best CRO and interact with academic experts to evaluate potential assets.
  • In collaboration with clinical development, define translational strategy on projects with the objective to guide clinical development: indication identification, patient stratification strategy, combination potential, optimization of dose selection, overall biomarker strategy, etc.
  • In partnership with clinical development, build the differentiation strategy for the therapeutic as well as defining the clinical and mechanism of action hypothesis and disease indication selection for early clinical development.
  • Contribute to hypothesis-driven study design, execution, and data analysis, including identification of most relevant preclinical and ex vivo models.
  • Identify key scientific questions in the projects and builds translation sciences plan according to their priority level.
  • Partner with BD and bring scientific expertise to evaluate and triage external assets and opportunities, identify main risk and mitigation plan and build additional evidence to enable Go/No Go decisions.
  • Partner with Innovation Lab team to prioritize various hypothesis, identify possible assets, generate evidence to enable advancement into clinical development.
  • Build open relationships with peers and external partners to ensure best decision making.
Desired Qualifications
  • Experience in clinical sciences, including contribution to clinical trials or to observational clinical studies in an academic or industry setting.
  • Track record of success and measurable contribution in moving ophthalmology therapeutic programs forward through preclinical and/or clinical development in an academic or industry setting.
  • Experience in research and/or development of anterior and/or posterior eye care segment therapies.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution for treating Demodex Blepharitis, a condition affecting the eyelids. The company also has a pipeline of potential treatments for Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong commitment to ethical practices and compliance. Their goal is to provide effective treatments for patients suffering from these conditions while expanding their product offerings through research and strategic partnerships.

Company Size

201-500

Company Stage

IPO

Total Funding

$58.4M

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing awareness of Demodex blepharitis expands market for Tarsus's XDEMVY.
  • Telemedicine rise offers new marketing opportunities for Tarsus's products.
  • FDA's focus on unmet needs may expedite Tarsus's pipeline approvals.

What critics are saying

  • Increased competition in ophthalmic treatments challenges Tarsus's market position.
  • Potential clinical trial delays could affect Tarsus's product pipeline.
  • Supply chain constraints may hinder XDEMVY's production and distribution.

What makes Tarsus Pharamceuticals unique

  • Tarsus focuses on high unmet needs in ophthalmic and infectious diseases.
  • Their lead product, XDEMVY, is FDA-approved for Demodex blepharitis treatment.
  • Tarsus's pipeline includes innovative treatments for Lyme disease and Rosacea.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

0%

2 year growth

1%
MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

The Manila Times
Nov 13th, 2024
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus welcomes Kate Goodrich, M.D., MHS, to its Board of Directors.

Vision Monday
Nov 12th, 2024
Tarsus Pharmaceuticals Appoints Elizabeth Yeu, MD, as Chief Medical Officer

IRVINE, Calif.- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company that applies proven science and new technology to eyecare to improve treatment for patients, has announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024.

Fierce Pharma
Aug 14th, 2024
Tarsus 'firing on all cylinders' as Xdemvy launch, sales force expansion roll ahead: CEO

Meanwhile, Tarsus in April picked up $200 million in financing from Pharmakon Advisors, on top of the $180 million equity offering the company pulled off earlier in the year.

Yahoo Finance
Apr 23rd, 2024
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP.